# FDA Inspection 1174494 - Regenerative Biologics, Inc. - July 14, 2022

Source: https://www.keypedia.com/records/fda_inspections/regenerative-biologics-inc/ebe7a2d1-cf9e-46cf-8f3f-2af36792a4c5
Source feed: FDA_Inspections

> FDA Inspection 1174494 for Regenerative Biologics, Inc. on July 14, 2022. Classification: No Action Indicated (NAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1174494
- Company Name: Regenerative Biologics, Inc.
- Inspection Date: 2022-07-14
- Classification: No Action Indicated (NAI)
- Project Area: Human Cellular, Tissue, and Gene Therapies
- Product Type: Biologics
- Office Name: Center for Biologics Evaluation and Research

## Related Documents

- [FDA Inspection 1174494 - 2022-07-14](https://www.keypedia.com/records/fda_inspections/regenerative-biologics-inc/3af86721-b4d0-4c62-9d85-ce397873c6d7)
- [FDA Inspection 1174494 - 2022-07-14](https://www.keypedia.com/records/fda_inspections/regenerative-biologics-inc/b5569cf2-7a89-4277-b34a-25f2ce54d137)
- [FDA Inspection 1069107 - 2018-09-19](https://www.keypedia.com/records/fda_inspections/regenerative-biologics-inc/547642fb-0278-400e-af81-fa11b42ff405)

Company: https://www.keypedia.com/companies/regenerative-biologics-inc/f6ef7b7e-79d0-4c32-95cf-342cf397c15e

Office: https://www.keypedia.com/offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d